LPL Financial LLC Increases Position in Catalyst Pharmaceuticals, Inc. $CPRX

LPL Financial LLC raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 28.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,229 shares of the biopharmaceutical company’s stock after purchasing an additional 16,246 shares during the period. LPL Financial LLC owned 0.06% of Catalyst Pharmaceuticals worth $1,800,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of CPRX. Castlekeep Investment Advisors LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at approximately $37,494,000. Bank of America Corp DE increased its position in shares of Catalyst Pharmaceuticals by 139.5% in the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company’s stock valued at $32,741,000 after purchasing an additional 913,843 shares during the last quarter. Allianz Asset Management GmbH grew its position in shares of Catalyst Pharmaceuticals by 397.8% in the 1st quarter. Allianz Asset Management GmbH now owns 694,125 shares of the biopharmaceutical company’s stock valued at $16,833,000 after buying an additional 554,674 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $6,887,000. Finally, Victory Capital Management Inc. grew its position in shares of Catalyst Pharmaceuticals by 82.3% in the 1st quarter. Victory Capital Management Inc. now owns 539,782 shares of the biopharmaceutical company’s stock valued at $13,090,000 after buying an additional 243,702 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $20.34 on Thursday. The stock has a market capitalization of $2.49 billion, a PE ratio of 12.33, a price-to-earnings-growth ratio of 0.82 and a beta of 0.70. The company has a fifty day moving average of $21.41 and a 200-day moving average of $22.64. Catalyst Pharmaceuticals, Inc. has a one year low of $19.00 and a one year high of $26.58.

Analyst Ratings Changes

A number of research firms recently commented on CPRX. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 9th. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 5th. Two investment analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $33.20.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 1,600 shares of the firm’s stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the sale, the insider owned 41,081 shares in the company, valued at $1,085,360.02. This trade represents a 3.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.40% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.